Clinical trial data and post-marketing surveillance indicate that a subset of patients experience decreased energy, tiredness, and general malaise while taking these medications
92% of Symptoguard users reported reduction in nausea symptoms compared to placebo (24%) 90% of Symptoguard users would recommend it to other GLP-1 users compared to placebo (22%) 52% SymptoGuard users estimated the side effects from their GLP-1 medications were reduced by 52% 52% of Symptoguard users reported a reduction in dizziness compared to placebo (16%) 78% of Symptoguard users reported a reduction in fatigue compared to placebo (27%) These statements have not been evaluated by the Food and Drug Administration
Due to this, only injectable forms of semaglutide are recommended during breastfeeding
These peptides remain research tools requiring substantial additional investigationincluding direct combination studies and eventual human trialsbefore any therapeutic applications could be considered
Freeze rules: do not repeatedly freezethaw a reconstituted solution
Abbreviations GalN: D-galactosamine GP: Glutathione peroxidase GR: Glutathione reductase GSH: Reduced glutathione GSSG: Oxidized glutathione GCS: -glutamylcysteine synthetase GCS-HS: Catalytic (heavy) subunit of-glutamylcysteine synthetase GCS-LS: Regulatory (light) subunit of-glutamylcysteine synthetase SOD: Superoxide dismutase IL-6: Interleukin-6 STAT3: Signal transducer and activator of transcription 3 TNF-: Tumor necrosis factor- NF-B: Nuclear factor kappa B GOT: Glutamic oxaloacetic transaminase GPT: Glutamic pyruvic transaminase ROS: Reactive oxygen species NOS: Nitric oxide synthase G6PD: Glucose-6-phosphate dehydrogenase 6PGD: 6-phosphogluconate dehyderogenase HMP: Hexose monophosphate pathway References Akerboom TP, Bilzer M, Sies H (1982) The relationship of biliary glutathione disulfide efflux and intracellular glutathione disulfide content in perfused rat liver